Please assess the completion status of the following clinical trial:

Trial Title: Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the uterine cervix~  * Stage IB2, IIA, IIB, IIIB, or IVA disease~    * Stage IIA tumors must be \> 4 cm~ * Primary, untreated disease~* Negative, non-suspicious para-aortic nodes by lymphangiogram, CT scan, MRI, or lymphadenectomy~* Must have been adequately clinically staged~* Suitable for treatment with radical intent using concurrent chemotherapy and pelvic radiotherapy~* No disease involvement of the lower third of the vagina regardless of stage (all stage IIIA, IIIB and IVA with lower one-third involvement)~* No carcinoma of the cervical stump~* Performance status - GOG 0-3~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* SGOT ≤ 3 times ULN~* Alkaline phosphatase ≤ 3 times ULN~* Creatinine ≤ ULN or calculated creatinine clearance ≥ 60mL/min~* No New York Heart Association class III-IV heart failure~* No history of myocardial infarction~* No unstable angina~* No uncontrolled hypertension~* No pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No septicemia or severe infection~* No other invasive malignancy within the past 5 years except nonmelanoma skin cancer~* No prior hysterectomy or planned hysterectomy as part of initial cervix cancer therapy~* No prior coronary artery bypass surgery~* No prior cancer therapy that would preclude study treatment~* No concurrent angina medication~* No concurrent intensity-modulated radiotherapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (cisplatin) (Type: ACTIVE_COMPARATOR): Patients receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 (weeks 1-6).
- Arm II (cisplatin, tirapazamine) (Type: EXPERIMENTAL): Patients receive tirapazamine IV over 2 hours on days 1, 8, 10, 12, 15, 22, 24, 26, and 29 and cisplatin IV over 1 hour on days 1, 15, and 29.

Based on this trial design, predict the completion outcome and termination type (if applicable).